Focal Segmental Glomerulosclerosis Clinical Trials

77 clinical trials for Focal Segmental Glomerulosclerosis across international registries, including 25 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants — RECRUITING · PHASE3
• An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis — RECRUITING · PHASE2
• A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) — RECRUITING · PHASE2
• A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) — RECRUITING · PHASE3
• Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases — RECRUITING · PHASE2
• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — RECRUITING · PHASE2
• NEPTUNE Match Study — RECRUITING · NA
• Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases — RECRUITING · PHASE2
• Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease — RECRUITING
• A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) — RECRUITING · NA
• taVNS for FRNS in Children — RECRUITING · NA
• SLIT ABS: Study on Patients With Autoimmune Podocytopathy — RECRUITING · NA
• A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis — RECRUITING · PHASE2
• AMPK-activation by Metformin in FSGS: AMP-FSGS — RECRUITING · PHASE1
• A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFECTS OF ORAL TRPC6 INHIBITOR BI 764198 TAKEN OVER A 104 WEEK TREATMENT PERIOD IN ADULT AND ADOLESCENT PARTICIPANTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (PFSGS) OR GENETIC FSGS RELATED TO TRPC6 GENE VARIANTS — RECRUITING
• Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children — RECRUITING · NA
• Raman Spectroscopy Diagnosis of Kidney Diseases — RECRUITING
• A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects — RECRUITING · PHASE1
• Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System — RECRUITING · NA
• A PARALLEL-GROUP TREATMENT, PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED UMBRELLA STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FREXALIMAB, SAR442970, AND RILZABRUTINIB IN PARTICIPANTS AGED 16 TO 75 YEARS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) OR MINIMAL CHANGE DISEASE (MCD) — RECRUITING · PHASE2
• ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank — RECRUITING
• National Registry of Rare Kidney Diseases — RECRUITING
• KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis — RECRUITING
• AN ADAPTIVE, PHASE 2 TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-0670512 FOLLOWING MULTIPLE INJECTIONS IN ADULT SUBJECTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) — RECRUITING · PHASE2
• STUDY OF LOSMAPIMOD TO REDUCE PROTEINURIA IN CORTICOSTEROID OR CALCINEURIN INHIBITOR RESISTANT IDIOPATHIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) — RECRUITING
• Genetic Markers for Focal Segmental Glomerulosclerosis — COMPLETED
• A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis — NOT_YET_RECRUITING · PHASE3
• Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome — COMPLETED
• Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis — ACTIVE_NOT_RECRUITING · PHASE4
• Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure — ACTIVE_NOT_RECRUITING
• Atrasentan in Patients With Proteinuric Glomerular Diseases — ACTIVE_NOT_RECRUITING · PHASE2
• Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) — COMPLETED · PHASE3
• A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) — OTHER · PHASE3
• Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis — COMPLETED · PHASE2
• PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant — COMPLETED · PHASE1
• A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX — COMPLETED · PHASE2
• Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis — COMPLETED · PHASE2
• Rituximab Treatment of Focal Segmental Glomerulosclerosis — WITHDRAWN · PHASE2
• A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome — TERMINATED · PHASE2
• A Study of CCX140-B in Subjects With FSGS — COMPLETED · PHASE2
• Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment — COMPLETED · PHASE1
• Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease — COMPLETED · PHASE2
• A multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics profile of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomerulosclerosis. — OTHER · PHASE2
• Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1 — OTHER
• Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) — TERMINATED · PHASE2
• A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) — TERMINATED · PHASE2
• Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) — COMPLETED
• LDL-Apheresis for FSGS CardioRenal Outcomes — COMPLETED
• A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147 — COMPLETED · PHASE1
• Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan — COMPLETED · PHASE2

Refine this search